Chris Fashek

Board of Directors, Argentum Medical

Chris Fashek is a board member of Argentum Medical, a Shore Capital portfolio company. Chris is an accomplished healthcare executive with a winning record of leading billion dollar global medical-device and pharmaceutical businesses. While CEO and Vice Chairman of KCI, Chris became recognized as a visionary and pioneer in the wound care sector by introducing V.A.C. Therapy, a negative pressure wound therapy (“NPWT”) technique, to both the physician community and patient population. This technique largely improved wound care for patients on a world-wide scale. KCI is known as a very successful private equity investment in the wound care, which will provide invaluable experience to SCP Wound Care. He recently transitioned from Board Member to Chairman and CEO for Spiracur, a privately held medical device company focused on the development of innovative wound healing technologies. In this role, Chris determines the strategy and manages the executional excellence credited for the company’s explosive growth.

Chris holds an MBA from Fairleigh Dickinson University and a BA in History from Upsala College.

Current and Past Board Roles

Areas of Focus

  • Advanced Wound Care